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Abstract  
Aims: Troponins I and T are biomarkers used 
for diagnosing myocardial infarction. The recently 
developed high-sensitivity Troponin T assay can 
detect levels as low as 3 ng/L which gives the 
advantage of rapid diagnosis of acute coronary 
syndrome (ACS) allowing earlier intervention and 
theoretically earlier discharge. The aim of the study 
was to audit the hospital practice and its adherence 
to international guidelines in using Troponin for 
diagnosing ACS, and to assess the average hospital 
admission length when using Troponin T compared 
to the older Troponin I. 
Methodology: A retrospective study that 
included all patients who had Troponin T taken 
between January 1st and January 31st, 2016 at Mater 
Dei Hospital (MDH), comparing them to patients 
who had Troponin I taken between November 1st 
and November 30th, 2015. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results: Data collection yielded a total of 
1,032 patients in the Troponin T group and 1,004 
patients in the Troponin I group. The average length 
of stay when using Troponin T was 6.42 days 
whereas the average length of stay when using 
Troponin I was 7.16 days. Data analysis of those 
patients also showed that the average time interval 
between the first and second Troponin was in the 
region of 9 hours, which is not what the current 
guidelines recommend. 
Conclusion: The use of the new highly 
sensitive Troponin T resulted in an average 
reduction in hospitalization time of 0.75 days per 
patient at MDH. Adherence to the “0/3 hours” 
guideline of the second Troponin is highly 
recommended. 
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Introduction 
Myocardial infarction (MI) is a leading cause 
of death and disability worldwide. Patients 
presenting with chest pain account for the second 
most common reason for emergency 
department visits in the United States, although 
only 20% of them are eventually found to suffer 
from acute coronary event.1 Cardiac Troponin T 
(cTnT) and troponin I (cTnI) are enzymes used to 
confirm or rule out a diagnosis of myocardial 
infarction (MI) alongside a history of typical chest 
pain and ECG abnormalities. They are coded by 
specific genes and are deemed to be unique to the 
myocardium.2 
The recent development of high sensitivity 
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Troponin Positive 
Ischemic 
Non-ACS: hypoxia, 
hypoperfusion, spasm
ACS: STMEI, Non-
STMEI
Non-ischemic
Cardiac: CHF, 
myocarditis, 
pericarditis, surgery 
Non-Cardiac: PE, 
trauma, renal failure, 
sepsis, SAH
cardiac troponin T (hs-cTnT) permits the detection 
of very low levels in the blood, which allows for a 
higher diagnostic accuracy in patients with 
suspected MI.3 In addition, the early identification 
of individuals at risk for MI is vital because patients 
benefit the most from early and aggressive 
treatment.4 In the past there were no set criteria on 
what a high sensitivity assay included, but this was 
resolved in 2012 after experts agreed on a 
definition: “high‐sensitivity assays should have a 
coefficient of variance (CV) of <10% at the 99th 
percentile value in the population of interest. To be 
classified as high‐sensitivity assays, concentrations 
below the 99th percentile should be detectable 
above the assay's limit of detection for >50% of 
healthy individuals in the population of interest”.5 
Hs-cTnT is an extremely sensitive blood test for the 
diagnosis of MI but not as specific; several other 
conditions can cause a false positive result. This 
could create a challenge when trying to correlate a 
raised level of hs-cTnT and clinical findings, as 
illustrated in (Figure 1).5 A meta-analysis involving 
9 studies and 9186 patients estimated a sensitivity 
of 0.94 (95% confidence interval [CI] 0.89-0.97) 
and a specificity of 0.73 (95% CI 0.64-0.81) for hs-
cTnT in diagnosing acute MI presentation to the 
emergency department.6 
 
 
Figure 1: Illustrates causes of Troponin rise 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is vital that a blood sample is drawn for 
cardiac troponin from all patients presenting with 
acute chest pain to the Emergency Department. 
According to the 2013 ESC guidelines for the 
management of non-ST elevation MI (NSTEMI), if 
hs-cTn is being used for the assessment of these 
patients, the time span between the first hs-cTn and 
the re-test hs-cTn should be 3 hours rather than the 
previously adhered to 6 hour time span. This 
facilitates an earlier rule in and rule out of ACS 
which leads to earlier intervention if necessary, or 
earlier discharge.7 
In Malta, hs-cTnT was introduced to Mater 
Dei Hospital in December 2015. Prior to this date, 
cTnI was the cardiac enzyme used to diagnose or 
rule out MI.  
 
Methods 
This study had two aims: the first was to 
compare hospitalization time between patients 
admitted with suspected MI before and after the 
introduction of hs-cTnT, and the second was to 
audit the time span between the first cardiac 
Troponin and the follow up Troponin, and whether 
the ESC guidelines were being adhered to in 
Malta’s main public hospital.  
This research was conducted as a retrospective 
study with inclusion criteria encompassing all 
patients attending Mater Dei Hospital between 
November 1st 2015 and November 30th 2015 who 
had two or more cTnI samples taken. These were 
subsequently compared with patients attending 
between January 1st 2016 and January 31st 2016 
who had two or more hs-cTnT samples taken. 
Patients who only had one troponin taken were 
excluded from this study.  
The data was gathered from the Mater Dei 
Hospital medical computer records system (iSoft). 
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Exclusion criteria were applied manually by the 
authors during data analysis.  
 
Results 
In the cohort of patients between 1st 
November and 30th November 2015 there were 
1005 patients. 566 were male (age range 10-95 
years) and 439 were female (age range 16-100 
years). In the cohort of patients between 1st January 
and 31st January 2016 there were 1031 patients. 571 
were male (age range 14-97 year) and 460 were 
female (age range 18-98 years). Figure 2 compares 
the gender differences between both populations, 
while figures 3 and 4 compare the age differences. 
The average time span between Troponin I 
tests that were taken was 9.26 hours (approximately 
9 hours and 15 minutes) while the average time 
span between Troponin T tests that were taken was 
9.14 hours (approximately 9 hours and 8 minutes). 
This resulted in an average reduction of 7 minutes 
(P value 0.0001). 
The average length of stay for patients being 
investigated for suspected Acute Coronary 
Syndrome whilst using the Troponin I assay was 
7.16 days, with a median length of 3 days, and this 
was reduced to 6.42 days with a median length of 2 
days after the introduction of the new high-
sensitivity Troponin T assay. This was an average 
reduction in length of stay of 0.74 days per hospital 
patient admission (18 hours approximately). 
 
 
 
Figure 2: Illustrates the gender differences between both populations 
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Age groups in the troponin I population
80 - 100 60 - 80 40 - 60 20 - 40  10 - 20
Figure 3: Illustrates the age groups in the first group (Troponin I population) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Illustrates the age groups in the second group (Troponin T population) 
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Discussion 
In Malta there is no single, consistent 
guideline to define the time period between taking 
serial Troponin T tests in the setting of a suspected 
Acute Coronary Syndrome. The current UK and 
European Guidelines state that the time period 
between Troponin 1 and 2 should be three hours. As 
can be seen from the results, before the introduction 
of the new high sensitivity Troponin T test the 
average time between Troponin I tests was 9.26 
hours. After the introduction of the Troponin T 
tests, a small but significant impact on this time 
delay was observed, reducing it to 9.14. The reason 
why there wasn’t a significant difference in the 
interval between the two tests could be attributed to 
the hospital policy at the time which still 
recommended a repeat test to be done after a six 
hour, rather than a three hour, window. We strongly 
recommended the implementation of change in this 
policy and repeating the 2nd hs-cTnT in three hours 
rather than six. 
Prior to the introduction of the Troponin T 
high sensitivity assay, the average length of stay at 
hospital for patients being investigated for 
suspected Acute Coronary Syndrome was 7.16 
days. With the introduction of the high sensitivity 
assay this length of stay reduced to 6.42 days. An 
average reduction of 0.74 days (18 hours 
approximately) was achieved with P value less than 
0.018. Based on 2012 national figures published in 
the Times of Malta, the average cost of a bed in a 
Medical/Cardiac ward varied from 164.68 Euros to 
278.87 (mean 221.78).8 The reduction in time scale 
of 18 hours with regards to length of admission 
with the introduction of the Troponin T assay 
therefore equates to an average saving of 164.12 
Euros per patient admission. Taking into account 
the fact that during January 2017 the number of 
patients admitted or already an in-patient but having 
serial Troponin tests taken was 32.23/day, if each of 
these patients spent an average 18 hours less as an 
in-patient, this equates to 23.85 days per month of 
bed-time saved. This would save an average of 
5,289.50 Euros per day to the local health service; 
equating to 63,473.97 Euros per year. It is, 
however, too early to tell whether the introduction 
of hs-cTnT had an impact on mortality rates. This 
could be a potential aim for a future study. 
Some randomized controlled trials have 
demonstrated the safety and the high efficacy of 
early patient discharge in accelerated 2-hour 
protocols when compared to standard care. If we are 
to standardize such protocols in the Malta health 
casualty service, the number of admissions will be 
expected to further decrease with significant 
economic benefits.9 
 
Limitations 
The design of our study does not come 
without a few limitations. The first of those was that 
other factors were noted to come into play when 
analyzing the length of stay of patients presenting 
with chest pain. Some patients in our cohort had a 
prolonged length of stay due to having multiple co-
morbidities and having other diagnoses than ACS, 
making it necessary in their cases to prolong the 
length of their inpatient stays. In a few cases it was 
not possible to attribute differences in length of stay 
to the different Troponin assays. Another factor 
which might have confounded the interpretation of 
our results is the fact that overcrowding of hospital 
beds in January might have influenced an earlier 
discharge date for patients presenting the same way 
as those who presented in November, where less 
pressure for beds was present.  
Another limitation was that in many cases a 
clear “clinical reason for request” was not 
adequately provided by the clinician requesting the 
Troponin blood test, in many cases sufficing with a 
simple “follow-up”. For that reason it was not 
understood why a Troponin was taken in patients as 
young as 10 years, for example. 
We did not include the diagnosis of patients 
included in this study or their outcomes as we did 
not deem it consistent with our scope and aims. We 
also did not look into time to intervention for 
patients who ended up being diagnosed with acute 
MI, although that could be a promising discussion 
point for another paper. 
  
Conclusion  
Based on our study, the introduction of high-
sensitivity Troponin T for the assessment of acute 
coronary syndrome in Malta did result in a 
statistically significant reduction of hospitalization 
time and was thus cost effective. Further steps are 
advised to be taken to ensure adherence to the 
recent European guidelines of the second Troponin 
timing. We advise that patients presenting with 
symptoms suggestive of ACS have their first 
Troponin taken at the triage stage during the first 
encounter, which allows the second Troponin to be 
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taken 3 hours later. This will facilitate either earlier 
discharge and, if needed, earlier intervention. 
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